These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 1518726

  • 1. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations.
    Petros WP, Rodman JH, Relling MV, Christensen M, Pui CH, Rivera GK, Evans WE.
    Pharmacotherapy; 1992; 12(4):273-7. PubMed ID: 1518726
    [Abstract] [Full Text] [Related]

  • 2. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
    Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):71-7. PubMed ID: 1731053
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
    Petersen KB, Jusko WJ, Rasmussen M, Schmiegelow K.
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
    [Abstract] [Full Text] [Related]

  • 4. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
    Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C, Kornegay N, Pui CH, Relling MV.
    J Clin Oncol; 2008 Apr 20; 26(12):1932-9. PubMed ID: 18421047
    [Abstract] [Full Text] [Related]

  • 5. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD.
    Pediatr Blood Cancer; 2006 Feb 20; 46(2):179-86. PubMed ID: 16007607
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.
    Kearns CM, Blakley RL, Santana VM, Crom WR.
    Cancer Res; 1994 Mar 01; 54(5):1235-9. PubMed ID: 7906999
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, de Koning J, van Zanen GE.
    Am J Pediatr Hematol Oncol; 1989 Mar 01; 11(2):125-33. PubMed ID: 2665546
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of serum protein binding of felodipine.
    Valle M, Esteban M, Rodríguez-Sasiaín JM, Calvo R, Aguirre C.
    Res Commun Mol Pathol Pharmacol; 1996 Oct 01; 94(1):73-88. PubMed ID: 8948016
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A.
    Cancer; 2008 May 01; 112(9):1983-91. PubMed ID: 18318429
    [Abstract] [Full Text] [Related]

  • 11. Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.
    Rodman JH, Furman WL, Sunderland M, Rivera G, Evans WE.
    J Clin Oncol; 1993 Feb 01; 11(2):287-93. PubMed ID: 8426206
    [Abstract] [Full Text] [Related]

  • 12. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Sancho JM, Ribera JM, Xicoy B, Morgades M, Oriol A, Tormo M, del Potro E, Debén G, Abella E, Bethencourt C, Ortín X, Brunet S, Ortega-Rivas F, Novo A, López R, Hernández-Rivas JM, Sanz MA, Feliu E, PETHEMA Group.
    Eur J Haematol; 2007 Feb 01; 78(2):102-10. PubMed ID: 17087744
    [Abstract] [Full Text] [Related]

  • 13. Increased teniposide clearance with concomitant anticonvulsant therapy.
    Baker DK, Relling MV, Pui CH, Christensen ML, Evans WE, Rodman JH.
    J Clin Oncol; 1992 Feb 01; 10(2):311-5. PubMed ID: 1732431
    [Abstract] [Full Text] [Related]

  • 14. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
    Rivera GK, Evans WE.
    Semin Oncol; 1992 Apr 01; 19(2 Suppl 6):51-8. PubMed ID: 1411639
    [Abstract] [Full Text] [Related]

  • 15. [Allergic reactions to teniposide (VM-26) in children with neoplasms].
    Wysocki M, Nowaczyk-Michalak A, Pilecki O.
    Wiad Lek; 1992 Feb 01; 45(3-4):91-3. PubMed ID: 1413803
    [Abstract] [Full Text] [Related]

  • 16. Quantitative contribution of endogenous compounds and hypoalbuminemia in reducing the binding of furosemide in the plasma of newborn infants.
    Viani A, Pacifici GM.
    Dev Pharmacol Ther; 1992 Feb 01; 18(1-2):39-43. PubMed ID: 1483361
    [Abstract] [Full Text] [Related]

  • 17. Teniposide for acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 1992 Nov 13; 34(883):105-6. PubMed ID: 1435505
    [No Abstract] [Full Text] [Related]

  • 18. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
    Imbs DC, Paludetto MN, Négrier S, Powell H, Lafont T, White-Koning M, Chatelut E, Thomas F.
    Invest New Drugs; 2016 Feb 13; 34(1):41-8. PubMed ID: 26572909
    [Abstract] [Full Text] [Related]

  • 19. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.
    McLeod HL, Baker DK, Pui CH, Rodman JH.
    Cancer Chemother Pharmacol; 1991 Feb 13; 29(2):150-4. PubMed ID: 1760858
    [Abstract] [Full Text] [Related]

  • 20. Low levels of serum transport proteins indicate catabolic protein status during induction therapy for acute lymphoblastic leukemia.
    Koskelo EK, Saarinen UM, Siimes MA.
    Pediatr Hematol Oncol; 1991 Feb 13; 8(1):53-9. PubMed ID: 1903045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.